Design of dual JAK/ HDAC inhibitors as potent anticancer

agents
 Introduction
Single Inhibitors
HDAC inhibitors JAK inhibitor

CHALLENGES

Drug resistance

The Need
Restriction to Multi- Cancers are heterogeneous and driven by multiple
haematological target genetic abnormalities. Two or multiple targets are
malignancies necessary to fight against malignant cancers
 Introduction
• Multidrug-resistant cells have a higher activity of JAK/STAT signaling and an increased autocrine production of
STAT3-dependent cytokines than chemosensitive cells as shown in Fig.1 (Campia et al., 2015)
• HDAC inhibitors downregulated the expression of JAK2 V617F mutation protein and suppressed downstream
signaling to selectively influence the proliferation and growth of tumor cells bearing the JAK2 V617F mutation
over normal cells (Bareng et al., 2007)
• HDAC inhibitors were reported to downregulate STATs levels (Cardama et al., 2012)
• HDAC inhibitor could degrade proteasomal of JAK2 chaperone client oncoproteins to induce leukemic cell
apoptosis and demonstrated clinical benefits in AML but only acquired moderate efficacy as a single agent
(Buchwald et al., 2010)
• A phase Ib trial of Ruxolitinib in combination with Panabinostat to treat patients with MF showed good tolerance
and significant relief of symptoms, demonstrating great potential therapeutic value for treating MPNs
(NCT01433445 and NCT01693601) (Harrison et al., 2015)
• A combination of Pacritini and HDAC inhibitor Pracinostat substantiated synergistic antitumor effects in Fig. 1: western blot
preclinical mouse models of AML, implying the possible clinical application of simultaneous inhibition on JAK displaying overexpression of
JAK1 in A549/dx (resistant
and HDAC strategy for AML (Diermayr et al., 2012) cell line) compared to
chemosensitive cell line.
 JAK-HDAC
Dual Inhibitors
 Hypothesis

SAHA

Momelotinib

MS-275

HDAC inhibitor JAK inhibitor

JAK-HDAC Dual Inhibitor

 Objectives

1. Design, synthesis, and characterization of JAK-HDAC dual inhibitor

2. To perform in-silico studies to determine the interactions of the test
compound with the enzymes
3. To evaluate the anti-cancer properties of the synthesized dual
inhibitor
4. To determine the inhibitory effect of the test compound on JAK and
HDAC activity
 Method
1. Literature Review
Wound
healing 7. JAK inhibitory assay
assay

MTT Western blot

Colony assay
formation
assay

Flow
cytometry
4. Drug Synthesis /
JAK-HDAC Characterisation
inhibitor

5. Anti-proliferative assay 6. HDAC inhibitory

2. Drug Design assay
Western blotting of acetyl H3
protein

3.In-silico studies 7
 Expected Outcomes/ Conclusion

In- • Docking and molecular dynamic simulation will predict the test compound
silic binding to HDAC isoforms and JAK subtypes.
o
stud
ies

Biol • Establish its activity as a potent anticancer agent

ogic • Provide insights into its cellular mechanism of action
al • Overcome multidrug resistance
Eval
uati
on
Enz
yme • Validate its activity as a dual JAK and HDAC inhibitor
inhi
bitio
n
 References
1. Shen, P., Wang, Y., Jia, X., Xu, P., Qin, L., Feng, X., ... & Qiu, Z. (2022). Dual-target Janus kinase (JAK) inhibitors: Comprehensive
review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases. European Journal of
Medicinal Chemistry, 239, 114551.
2. Bareng, J., Jilani, I., Gorre, M., Kantarjian, H., Giles, F. J., Hannah, A., & Albitar, M. (2007). A potential role for HSP90 inhibitors in
the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry. Leukemia & lymphoma, 48(11),
2189-2195.
3. Quintás-Cardama, A., Kantarjian, H., Estrov, Z., Borthakur, G., Cortes, J., & Verstovsek, S. (2012). Therapy with the histone
deacetylase inhibitor pracinostat for patients with myelofibrosis. Leukemia research, 36(9), 1124-1127.
4. Buchwald, M., Pietschmann, K., Müller, J. P., Böhmer, F. D., Heinzel, T., & Krämer, O. H. (2010). Ubiquitin conjugase UBCH8 targets
active FMS-like tyrosine kinase 3 for proteasomal degradation. Leukemia, 24(8), 1412-1421.
5. Harrison, C. N., Kiladjian, J. J., Heidel, F. H., Vannucchi, A. M., Passamonti, F., Hayat, A., ... & Ribrag, V. (2015). Efficacy, safety, and
confirmation of the recommended phase 2 starting dose of the combination of ruxolitinib (RUX) and panobinostat (PAN) in patients
(pts) with myelofibrosis (MF). Blood, 126(23), 4060.
6. Novotny-Diermayr, V., Hart, S., Goh, K. C., Cheong, A., Ong, L. C., Hentze, H., ... & Wood, J. M. (2012). The oral HDAC inhibitor
pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood
cancer journal, 2(5), e69-e69.